The new strategy focuses on regulating the upstream/downstream, such as treating MTAP-deficient tumor cells with L-alanine and antagonizing the A2A receptor or inhibiting CD73 to counteract extracellular adenosine signaling. This evidence concerns the gene MTAP and neoplasm.